Novartis AG announced collaboration with Sangamo to research gene therapies for the treatment of autism spectrum disease. The top two brands will partner to develop gene therapies and other brain problems for ASD treatments. The agreement between Novartis and Sangamo provided the Brisbane-based firm with a net worth of approximately USD 75 million to accomplish the milestones in its commercial development.
Axial Therapeutics announced that the company received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for their lead candidate named AB-2004, which is a gut targeted, molecular therapeutic being studied for the treatment of irritability associated with ASD.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5382
Published Date: Nov 20, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Growing government efforts on raising funds and awareness for autism as well as increasing research and development are the major factors driving the growth of the autism diagnostics market.
The market size of autism diagnostics is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.
The major players in the market are Novartis AG, Allergan, Merck & Co Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Bristol-Myer Squibb, Janssen Pharmaceuticals, Inc., and others.
The autistic disorder segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.